Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
EpimAb
Biotech
Almirall signs $210M deal with EpimAb to develop bispecifics
The money will give Almirall access to EpimAb Biotherapeutics’ Fabs-In-Tandem Immunoglobulin platform .
James Waldron
Oct 12, 2023 9:55am
EpimAb reels in $120M to propel 3 clinical-stage bispecifics
Mar 22, 2021 7:00pm
BIO: EpimAb bags $74M to build bispecifics pipeline
Jun 5, 2019 12:00am